PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Huber, K. ; Aichler, M. ; Sun, N. ; Buck, A. ; Li, Z.* ; Fernandez, I.E. ; Hauck, S.M. ; Zitzelsberger, H. ; Eickelberg, O. ; Janssen, K.P.* ; Keller, U.* ; Walch, A.K.

A rapid ex vivo tissue model for optimising drug detection and ionisation in MALDI imaging studies.

Histochem. Cell Biol. 142, 361-371 (2014)
DOI PMC
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
The aim of this study was to establish an ex vivo model for a faster optimisation of sample preparation procedures, for example matrix choice, in matrix-assisted laser desorption/ionisation (MALDI) drug imaging studies. The ionisation properties of four drugs, afatinib, erlotinib, irinotecan and pirfenidone, were determined in an ex vivo tissue experiment by spotting decreasing dilution series onto liver sections. Hereby, the drug signals were distinctly detectable using different matrix compounds, which allowed the selection of the optimal matrix for each drug. The analysis of afatinib and erlotinib yielded high drug signals with α-cyano-4-hydroxycinnamic acid matrix, whereas 2,3-dihydroxybenzoic acid was identified as optimal matrix for irinotecan and pirfenidone detection. Our method was validated by a MALDI drug imaging approach of in vivo treated mouse tissue resulting in corresponding findings, indicating the spotting method as an appropriate approach to determine the matrix of choice. The present study shows the accordance between the detection of ex vivo spotted drugs and in vivo administered drugs by MALDI-TOF and MALDI-FT-ICR imaging, which has not been demonstrated so far. Our data suggest the ex vivo tissue spotting method as an easy and reliable model to optimise MALDI imaging measurements and to predict drug detection in tissue sections derived from treated mice prior to the recruitment of laboratory animals, which helps to save animals, time and costs.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
2.927
0.871
14
14
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Maldi Imaging ; Drug Imaging ; Ex Vivo Tissue Model ; Maldi-ft-icr; Mass-spectrometry; Clinical-research; Brain-tissue; Inhibitor; Sections; Normalization; Pirfenidone; Metabolism; Erlotinib; Receptor
Sprache englisch
Veröffentlichungsjahr 2014
HGF-Berichtsjahr 2014
ISSN (print) / ISBN 0948-6143
e-ISSN 1432-119X
Zeitschrift Histochemistry and Cell Biology
Quellenangaben Band: 142, Heft: 4, Seiten: 361-371 Artikelnummer: , Supplement: ,
Verlag Springer
Verlagsort New York
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Pathology (PATH)
Institute of Lung Health and Immunity (LHI)
CF Metabolomics & Proteomics (CF-MPC)
Research Unit Analytical Pathology (AAP)
Translational Metabolic Oncology (IDC-TMO)
POF Topic(s) 30504 - Mechanisms of Genetic and Environmental Influences on Health and Disease
30202 - Environmental Health
30203 - Molecular Targets and Therapies
30205 - Bioengineering and Digital Health
Forschungsfeld(er) Enabling and Novel Technologies
Lung Research
Radiation Sciences
PSP-Element(e) G-500300-001
G-501600-001
G-505700-001
G-500390-001
G-501000-001
G-505000-006
G-521800-001
PubMed ID 24824474
DOI 10.1007/s00418-014-1223-0
WOS ID WOS:000341915600002
Erfassungsdatum 2014-05-17
[➜Korrektur melden]